1. Home
  2. DRD vs HAE Comparison

DRD vs HAE Comparison

Compare DRD & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DRDGOLD Limited

DRD

DRDGOLD Limited

HOLD

Current Price

$26.51

Market Cap

2.5B

ML Signal

HOLD

Logo Haemonetics Corporation

HAE

Haemonetics Corporation

HOLD

Current Price

$67.99

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRD
HAE
Founded
1895
1971
Country
South Africa
United States
Employees
3410
N/A
Industry
Precious Metals
Medical/Dental Instruments
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.8B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
DRD
HAE
Price
$26.51
$67.99
Analyst Decision
Strong Buy
Buy
Analyst Count
2
9
Target Price
$32.63
$84.13
AVG Volume (30 Days)
232.5K
879.1K
Earning Date
08-19-2026
05-07-2026
Dividend Yield
2.24%
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.05
Revenue
N/A
$910,373,000.00
Revenue This Year
$39.23
N/A
Revenue Next Year
$30.12
$5.23
P/E Ratio
$15.32
$32.78
Revenue Growth
N/A
N/A
52 Week Low
$13.08
$47.32
52 Week High
$39.37
$87.32

Technical Indicators

Market Signals
Indicator
DRD
HAE
Relative Strength Index (RSI) 44.11 70.70
Support Level $26.07 $48.98
Resistance Level $30.99 $86.72
Average True Range (ATR) 0.91 2.73
MACD -0.05 1.36
Stochastic Oscillator 20.03 95.35

Price Performance

Historical Comparison
DRD
HAE

About DRD DRDGOLD Limited

DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.

About HAE Haemonetics Corporation

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Share on Social Networks: